A description of self-medication with cannabis among adults with legal access to cannabis in Quebec, Canada

Abstract

Objective Cannabis is increasingly used for medical purposes, particularly in countries like Canada where cannabis was recently legalized for recreational use. We aimed to assess self-medication with cannabis post-cannabis legalization among adults in the Canadian province of Quebec. Methods This is a cross-sectional online survey of a self-selected convenience sample conducted in Quebec, Canada, from November 2020 to January 2021. Individuals aged ≥ 21 years who endorsed using cannabis bought in legal recreational cannabis stores to self-medicate a health condition were included. Data were analyzed using descriptive statistics and stratified according to sex, age, and the type of cannabis use (exclusively medical versus medical and recreational use). Results Four hundred eighty-nine participants were included. The median age was 34 years, and 48% were women. About 25% reported exclusive medical use of cannabis. Treated conditions included anxiety (70%), insomnia (56%), pain (53%), depression (37%), and many others. Reasons for not consulting in cannabis clinics included lack of information (52%), the complexity of the process (39%), accessibility of cannabis clinics (23%), and others. Tetrahydrocannabinol (THC) dosage > 20% was reported by 32%. Smoking was the main route of use (81%). Possession of prescribed drugs was reported by 56%. Professionals consulted for information on cannabis included recreational cannabis store agents (36%), physicians (29%), and others. Overall, significant differences were observed for many of the comparisons according to sex, age, and the type of cannabis use. Conclusions Many conditions are self-medicated with cannabis. The use of high doses of cannabis, smoking as a preferred method of use, and concurrent use of other medications may pose some risks to individuals. Addressing the reported barriers to medical access to cannabis is urgently needed.

A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years

“…The median daily dose of oral THC for the AECeR cohort is approximately 10% of the average recreational user. Recreational cannabis even for medical purposes is largely inhaled [32]. Inhaled cannabis is rapidly absorbed and reaches peak serum concentration (Cmax) in minutes giving the well-known "high".…”

Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review

“…Psychological distress refers to non-specific symptoms that include stress, anxiety and depression; increased levels of psychological distress may indicate the beginning of serious conditions such as major depressive disorder, anxiety disorder, schizophrenia, somatization disorder, or a variety of other clinical conditions [ 4 ]. In practice, it is often seen that many patients deny any symptoms of psychological distress [ 5 , 6 ] and often they self-treat with ethanol [ 7 ] and/or social recreational agents [ 8 ].…”

Cannabis use among workers with work-related injuries and illnesses: results from a cross-sectional study of workers’ compensation claimants in Ontario, Canada

“…Recent findings from the National Cannabis Survey also found that, among the 14% of Canadian respondents 16 years of age and over using cannabis for medical purposes, 78% did so without medical authorisation 40. Yet, some adults who self-medicate with cannabis also report a desire to access health professionals for advice related to their use 41. A qualitative study of family physicians demonstrated they were often hesitant to guide patients on medical cannabis use, including a reluctance to authorise its use, due to concerns about the potential for harm and a feeling they lacked education about its therapeutic benefit 42.…”